Fig. 6

Inhibition of PKA reverses the protective effect of EA on degenerative intervertebral discs. (A)The level of cAMP in the lumbar disc. (B)The level of PKA in the lumbar disc. (C)The protein levels of AQP1, AQP3, CREB, eIF-2, actin, MAP1A, MAP1B, MAP2, MAP4, and Tau in the lumbar disc. (D-M)The quantitative graphs of AQP1, AQP3, CREB, eIF-2, actin, MAP1A, MAP1B, MAP2, MAP4, and Tau. (N-W)The mRNA levels of AQP1, AQP3, CREB, eIF-2, actin, MAP1A, MAP1B, MAP2, MAP4, and Tau in the lumbar disc. Data are expressed as the mean ± SD. **P < 0.01, compared with the sham group; ##P < 0.01, compared with the model group.△△P < 0.01, △P < 0.05, compared with the EA group